Press Releases

  • Study Questions Benefits of Testosterone Replacement for Low T
    September 21, 2016

    The prescription of testosterone supplementation for cardiovascular health, sexual function, physical function, mood, or cognitive function in men with “low T” is not supported by clinical trials data, conclude researchers who describe a review of more than 200 clinical trials in PLOS One.

  • Math Difficulties May Reflect Problems in a Crucial Learning System in the Brain
    September 15, 2016

    Children differ substantially in their mathematical abilities. In fact, some children cannot routinely add or subtract, even after extensive schooling. Yet the causes of these problems are not fully understood. Now, two researchers, at Georgetown University Medical Center and Stanford University, have developed a theory of how developmental “math disability” occurs.

  • Tamoxifen Resistance Linked to High Estrogen Levels in Utero
    September 8, 2016

    WASHINGTON — An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals. The study provides a new path forward in human research as about half of the breast cancers treated with this common cancer therapy do not respond well, say researchers at the Georgetown Lombardi Comprehensive Cancer Center, who led the multi-institutional research.

  • MEDIA ADVISORY: 2016 Ruesch Center Policy Briefing: Fighting a Smarter War on Cancer
    September 5, 2016

    WASHINGTON – The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center hosts its 2016 Cancer Policy Briefing, Wednesday, September 14 from 9:00 to 11:30 a.m. at the Georgetown University Law Center.

  • Georgetown Medical Experts Available During Olympic Games
    August 5, 2016

    WASHINGTON -– Georgetown University Medical Center physicians and researchers are available to answer questions about medical topics related to athletes competing in the 2016 Olympic Games.

  • Collateral Harm: The Impact of Ebola and Related Fears on Facility-Based Child Deliveries
    August 2, 2016

    WASHINGTON -- The first known household survey examining the collateral harm to pregnancy services in areas affected by the West African Ebola epidemic suggests a significant slide backwards in child and maternal health. The study, conducted in Liberia, points to the deep disruptions caused by the Ebola epidemic — even in parts of the country with relatively limited transmission.

  • Switch from Observation Only to Active Treatment by Patients with Prostate Cancer Varies by Race and Ethnicity
    July 29, 2016

    NEW YORK, NY -- Assessment of clinical and nonclinical factors indicates that black men on active surveillance are more likely to pursue active treatment, according to a new study published in The Journal of Urology.

  • Zika Has Arrived, But is the U.S. Ready?
    July 29, 2016

    WASHINGTON –The Florida Department of Health, investigating non-travel related cases of Zika in Miami-Dade and Broward counties, has concluded “that a high likelihood exists that four cases are the result of local transmission.” Despite the advance warning of Zika’s approach, Georgetown experts in infectious disease, public health law, health systems readiness and mosquito research say the United States isn’t ready for a Zika outbreak. 

  • More Evidence in Quest to Repurpose Cancer Drugs for Alzheimer’s Disease
    July 27, 2016

    TORONTO – An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer’s and Parkinson’s diseases when given to animals. This finding is the latest from Georgetown University Medical Center’s Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

  • Resveratrol Appears to Restore Blood-Brain Barrier Integrity in Alzheimer’s Disease
    July 27, 2016

    TORONTO — Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, compared to a matching group of placebo-treated patients with the disorder.